Description
Methandrostenolone (Dianabol, D-Bol, Methandienone) is a synthetic testosterone derivative with 17α-methyl group and an additional double bond between positions 1 and 2 of the steroid scaffold. The substance was developed in 1958 by American endocrinologist John Ziegler in collaboration with CIBA, explicitly to improve athletic performance in olympic research applications.
Per study reports Dianabol binds to the androgen receptor and is converted to a mildly aromatizing metabolite. The aromatization rate is lower than testosterone itself but higher than DHT derivatives. This yields the classic Dianabol profile: rapid mass gain, marked water retention, visible pumps within 1-2 weeks.
Pharmacokinetically orally bioavailable with about 3-6 hour half-life. Typical research protocols therefore require 2-3 daily doses for stable plasma levels. Bioavailability is around 70-90% thanks to the 17α-methyl group reducing first-pass hepatic metabolism.
Known effects in studies: high hepatotoxicity (ALT/AST elevation consistently documented), hypertension, unfavorable lipid profile, gynecomastia research findings due to aromatization, HPG suppression. With longer cycles, liver damage in case reports.
In recreational research practice Dianabol is the classical kickstart compound for mass cycles. Typical 4-6 weeks at the start of a test-based research protocol while the test esters are flooding in.
Dianabol is on the WADA banned list.
You can order Methandrostenolone as oral tablets in one bottle with 50mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Methandrostenolone has one of the longest documented risk profiles of all anabolics and sits clearly in the upper range of the risk scale. The effects documented in the literature are well established and affect the liver, blood pressure and hormonal balance.
Documented in studies and the user literature:
- High liver strain: as a 17α-methyl steroid, Dianabol is hepatotoxic. ALT/AST elevations are consistently documented. Longer cycles show liver damage in case reports.
- Estrogen conversion: Dianabol partly aromatizes to estradiol. Water retention and gynecomastia findings are documented.
- Cardiovascular: studies describe hypertension and an unfavorable lipid profile.
- Suppression of natural production: suppression of the HPG axis is documented in the literature.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- “Anabolic” effects of methandienone in men undergoing athletic training - The Lancet 1976, Hervey et al: Classic controlled training study on strength and body composition effects of methandienone.
- Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol) - Clinical Science 1986, Godsland et al: Study on metabolic effects on insulin action.
- The anabolic steroid methandienone targets the hypothalamic-pituitary-testicular axis and myostatin signaling in a rat training model - Archives of Toxicology 2011, Mosler et al: Mechanism study on HPG suppression and myostatin signaling.
- Jaundice Due to Methandrostenolone Therapy - JAMA 1962, Kaupp et al: Early documentation of cholestatic liver toxicity.
- Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone) - Cancer 1977, Hernandez-Nieto et al: Case report on hepatic adenoma after long-term use.
